The Hindu - Home
U.S. FDA approves AbbVie's drug for Parkinson's disease
The drug tavapadon, which AbbVie gained access to through its $8.7 billion acquisition of Cerevel Therapeutics in 2023, comes as a once-a-day pill
Shown as published in the source's RSS feed. IndiaAIFounders doesn't link out to third-party sites — this is the complete detail available from the feed itself.